All In Biotech

Drug Trial Radar · NCT04023526

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

103

Actual

Start

Jul 29, 2019

Primary completion

Aug 15, 2023

Study completion May 15, 2027

Sponsor

Lead sponsor
OncoVerity, Inc.Industry
Sponsor type
Industry
Collaborators
argenx; Janssen Research & Development, LLC
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • AzacitidineDrug

    Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.

  • CusatuzumabDrug

    Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Complete Remission (CR)Time frame: Up to 3 years and 5 months

Locations

56 sites in 9 countries. Site status is shown where the registry gives one.

  • St Vincents Hospital Sydney

    Darlinghurst, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Australia

  • The Alfred Hospital

    Melbourne, Australia

  • Royal Perth Hospital

    Perth, Australia

  • Westmead Hospital

    Westmead, Australia

  • Universidade Estadual De Campinas

    Campinas, Brazil

  • Hospital das Clinicas de Porto Alegre

    Porto Alegre, Brazil

  • CHU d'Angers

    Angers, France

  • CHU Grenoble

    Grenoble, France

  • Institut Paoli Calmettes

    Marseille, France

  • Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie

    Pessac, France

  • CHU Lyon Sud

    Pierre-Bénite, France

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, France

  • CHRU Tours Hôpital Bretonneau

    Tours, France

  • Rambam Medical Center

    Haifa, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna

    Bologna, Italy

  • Azienda Ospedaliera Spedali Civili di Brescia

    Brescia, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

    Meldola, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • Division of Hematology, Cardarelli Hospital

    Naples, Italy

  • Azienda Sanitaria Universitaria Integrata di Udine

    Udine, Italy

  • Chelyabinck Regional Clinical Hospital

    Chelyabinsk, Russia

  • S.P. Botkin Moscow City Clinical Hospital

    Moscow, Russia

  • City Clinical Hospital # 40

    Moscow, Russia

  • Nizhniy Novgorod Region Clinical Hospital

    Nizhny Novgorod, Russia

  • Ryazan Regional Clinical Hospital

    Ryazan, Russia

  • St.-Petersburg Clinical Research Institute of Hematology and Transfusiology

    Saint Petersburg, Russia

  • City clinical hospital #15

    Saint Petersburg, Russia

  • Samara Region Clinical Hospital

    Samara, Russia

  • Oncologic Dispensary No.2

    Sochi, Russia

  • Komi Republic Oncology dispensary

    Syktyvkar, Russia

  • Ekaterinburg City Clinical Hospital # 7

    Yekaterinburg, Russia

  • Hosp. de La Santa Creu I Sant Pau

    Barcelona, Spain

  • Inst. Cat. Doncologia-H Duran I Reynals

    Barcelona, Spain

  • Hosp. Univ. Vall D Hebron

    Barcelona, Spain

  • Hosp. Reina Sofia

    Córdoba, Spain

  • Hosp. Univ. Ramon Y Cajal

    Madrid, Spain

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.